rs12188300 — IL12B

IL12B Near-Gene Variant — Psoriasis Risk and IL-12/23 Biology

The IL12B gene¹¹ IL12B gene
located at 5q33.3, encodes the 40 kDa p40 subunit (also called IL-12B) shared by two structurally related but functionally distinct cytokines: IL-12 and IL-23. IL-12 pairs p40 with the p35 subunit to form the IL-12 heterodimer that drives Th1 differentiation and IFN-γ production. IL-23 pairs the same p40 subunit with the p19 subunit (IL-23A) to form IL-23, which drives Th17 cell expansion and IL-17 production. Both pathways converge on psoriatic skin inflammation — IL-12/Th1 produces the keratinocyte-activating IFN-γ while IL-23/Th17 produces the epidermal-hyperproliferation-driving IL-17. The rs12188300 variant lies near the IL12B gene in a 5q33.3 intergenic regulatory region and has been independently associated with psoriasis vulgaris in German, Polish, and Russian populations²² independently associated with psoriasis vulgaris in German, Polish, and Russian populations
Hüffmeier et al. identified the IL12B locus in a German GWAS; Malinowski et al. confirmed rs12188300 specifically in Polish patients.

The Mechanism

rs12188300 falls within the 5q33.3 regulatory region flanking IL12B, a genomic neighborhood containing multiple psoriasis susceptibility variants. The IL12B locus harbors a well-characterised risk haplotype defined by rs6887695 (upstream) and rs3212227 (3′ UTR)³³ risk haplotype defined by rs6887695 (upstream) and rs3212227 (3′ UTR)
rs12188300 is in moderate linkage disequilibrium with this haplotype and may itself tag regulatory elements controlling IL12B transcription. Functional studies of the IL12B risk haplotype demonstrate that risk-allele carriers show increased IL12B expression in monocytes, leading to elevated serum IL-12 and IFN-γ but paradoxically decreased IL-23 levels⁴⁴ increased IL12B expression in monocytes, leading to elevated serum IL-12 and IFN-γ but paradoxically decreased IL-23 levels
This skews the inflammatory milieu toward Th1 rather than Th17, yet both arms contribute to psoriatic disease. The net effect is a stronger pro-inflammatory IL-12/IFN-γ axis in carriers, amplifying the [positive feedback loop | IL-12 drives IFN-γ production, which in turn upregulates CXCL10 and further activates T cells, sustaining chronic skin inflammation] visible in psoriatic plaques.

The Evidence

rs12188300 was identified as part of the broader IL12B/5q33.3 psoriasis susceptibility locus in genome-wide studies. The TRAF3IP2 discovery GWAS Hüffmeier et al., Nature Genetics 2010⁵⁵ Hüffmeier et al., Nature Genetics 2010
Identified TRAF3IP2 as a new PsA and psoriasis susceptibility locus included 609 psoriatic arthritis cases and 990 controls in the initial scan, with replication across 6 European cohorts (5,488 individuals total), and also replicated the IL12B locus association. The most detailed replication comes from a Polish case-control study of 507 psoriasis patients and 396 controls⁶⁶ Polish case-control study of 507 psoriasis patients and 396 controls
Malinowski et al., Postepy Dermatol Alergol 2022, which found a minor allele frequency of 11.8% in psoriatic patients versus 8.7% in controls (p = 0.036), with a dominant-model odds ratio of 1.53 (95% CI 1.09–2.16, p = 0.014). The IL12B locus as a whole is among the most robustly replicated psoriasis susceptibility loci: a meta-analysis of 11 studies Zhu et al., 2013⁷⁷ Zhu et al., 2013
Meta-analysis of IL12B polymorphisms with psoriasis and psoriatic arthritis confirmed the IL12B risk haplotype's association with psoriasis (OR ~1.4) and psoriatic arthritis (OR ~1.5). The IL12B locus is additionally shared with Crohn's disease and ulcerative colitis risk, consistent with the [epidemiological overlap between psoriasis and IBD | Patients with psoriasis are approximately twice as likely to have Crohn's disease compared to the general population].

Practical Actions

For T allele carriers, the IL12B locus's relevance extends beyond disease risk to treatment response. Ustekinumab (Stelara) is a monoclonal antibody that binds directly to the p40 subunit encoded by IL12B, blocking both IL-12 and IL-23 signaling simultaneously. An Italian pharmacogenomic study⁸⁸ An Italian pharmacogenomic study
Galluzzo et al., Dermatology 2016 found that specific IL12B genotypes significantly predicted ustekinumab response in HLA-Cw6 positive patients. Carriers of the IL12B risk haplotype (elevated p40 expression) provide more target for ustekinumab blockade, but the relationship between rs12188300 specifically and treatment response has not been isolated from haplotype-level effects. Guselkumab and risankizumab target only the p19 (IL-23 specific) subunit rather than p40, so their efficacy is not directly influenced by IL12B expression levels in the same way. Carriers with psoriasis or psoriatic arthritis should discuss genotype-informed biologic selection with their dermatologist or rheumatologist, as the IL12B locus may help stratify responses.

Gut inflammation implications also deserve attention: the shared IL12B susceptibility between psoriasis and IBD means T allele carriers with digestive symptoms (persistent diarrhea, abdominal pain, blood in stool) warrant evaluation for subclinical inflammatory bowel disease, given the comorbidity rate is roughly double that of the general population.

Interactions

rs12188300 (IL12B) and rs33980500 (TRAF3IP2) were both identified in the same German GWAS screen for psoriasis susceptibility, pointing to partially overlapping but distinct pathways. TRAF3IP2 encodes Act1, an adaptor protein in the IL-17 receptor signaling cascade downstream of Th17 cells. Individuals carrying risk alleles at both IL12B (rs12188300, elevated IL-12 p40 production and Th1/IFN-γ amplification) and TRAF3IP2 (rs33980500, impaired Act1 function removing the IL-17-dependent negative feedback on Th17 cells) may have compounded susceptibility: the IL12B variant amplifies the IL-12/Th1 axis and increases p40 availability, while the TRAF3IP2 variant removes the downstream brake on Th17 expansion, allowing unchecked IL-22-driven keratinocyte proliferation. rs11209026 (IL23R R381Q) encodes a loss-of-function receptor variant that is strongly protective against psoriasis and IBD by dampening IL-23 signaling. Carrying both the IL12B rs12188300 T risk allele and the IL23R rs11209026 protective A allele represents a partially antagonistic combination, where increased p40 availability may be partially offset by reduced receptor sensitivity. The combined effect would benefit from compound action analysis once all three variants are genotyped.